Navigation Links
Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI)
Date:9/15/2009

SAN DIEGO, Sept. 15 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that new data highlighting fidaxomicin's (OPT-80) lower CDI recurrence rates and reduced risk of vancomycin-resistant enterococci (VRE) acquisition from Optimer's North American phase 3 study were presented at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco.

(Logo:http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)

"The additional data highlight fidaxomicin's unique profile as a new antibiotic class with beneficial characteristics for treating CDI," said Michael N. Chang, Ph.D., President and CEO of Optimer Pharmaceuticals. "These analyses describe fidaxomicin's low recurrence rate, safety profile, potent activity against CDI, and minimal disruption to the normal intestinal flora. We think fidaxomicin has the potential to be the treatment of choice for CDI which is a serious unmet medical need with limited treatment options."

Yoav Golan, M.D., an investigator from the Tufts Medical Center in Boston, MA, presented additional analyses around the previously reported recurrence data showing that patients treated with fidaxomicin had a substantially lower recurrence rate (13.3%) than those treated with vancomycin (24.0%). However, the recurrence rate difference between fidaxomicin and vancomycin was even greater, 10.9% versus 24.3%, respectively, in patients who did not receive CDI therapy (either vancomycin or metronidazole) in the 24-hour pre-trial enrollment period. Dr. Golan further noted that CDI recurrence occurred significantly later in patients t
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
3. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... , September 2, 2015 ... market for global clinical trials review of H2, ... scenario with an objective to enhance decision making ... Complete report on Keratoconus market clinical trials ... companies, 10 institutes / government organizations and supported ...
(Date:9/1/2015)... Mass. , Sept. 1, 2015  Shareholder rights ... whether certain officers and directors of ConforMIS, Inc. (NASDAQGS: ... ConforMIS is a medical technology company that uses its ... joint replacement implants that are individually sized and shaped ... this press release on the law firm,s Shareholder Rights ...
(Date:9/1/2015)... , Sept. 1, 2015 On August 31, ... Jr. , issued a 123-page order in the first ... Medical Conserve metal-on-metal hip replacement devices are defective.[1]  ... judgment as to Plaintiff Robyn Christiansen,s claims for defective ... Court flatly rejected Wright Medical,s claim that the Medical ...
Breaking Medicine Technology:Keratoconus Market Clinical Trials Review H2 2015 Global Research Report 2Keratoconus Market Clinical Trials Review H2 2015 Global Research Report 3Keratoconus Market Clinical Trials Review H2 2015 Global Research Report 4Keratoconus Market Clinical Trials Review H2 2015 Global Research Report 5Robbins Arroyo LLP Is Investigating the Officers and Directors of ConforMIS, Inc. (CFMS) on Behalf of Shareholders 2Pope McGlamry: Omnibus order in Conserve Hips MDL-2329 sets stage for bellwether trial 2Pope McGlamry: Omnibus order in Conserve Hips MDL-2329 sets stage for bellwether trial 3
... LONDON, April 21, 2012 Medaxial, the ... won a Queen,s Award for Enterprise in recognition of ... for Enterprise are the UK,s most prestigious business accolade, ... select number of companies who have achieved outstanding results ...
... INC. (Nasdaq: PDEX ) announced today that ... of Chief Executive Officer, effective immediately.  The Company also ... positions with the Company and its subsidiaries, including his ... a member of the Company,s Board of Directors, effective ...
Cached Medicine Technology:Pharmaceutical Industry Service Company Awarded The UK's Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade 2Pharmaceutical Industry Service Company Awarded The UK's Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade 3Pro-Dex, Inc. Appoints Michael J. Berthelot Chief Executive Officer 2Pro-Dex, Inc. Appoints Michael J. Berthelot Chief Executive Officer 3
(Date:9/1/2015)... ... September 01, 2015 , ... Consumers overwhelmingly prefer to ... Dermatologic Surgery, according to a new survey that also offers insight on why ... Procedures – which reflects views on cosmetic medical treatments and ratings for 10 ...
(Date:9/1/2015)... , ... September 01, 2015 , ... ... “Hair Extension Vending Machine,” is still strongly maintaining her firm’s success in the ... beauty tools. In her upcoming city-to-city tour, Ellis will be providing “Look and ...
(Date:9/1/2015)... ... , ... The Jerry Segal Classic to benefit the patients of Magee Rehabilitation ... in Lafayette Hill, PA. Over the past 26 years, the Classic, organized by the ... designed to support patients and their families during their time at Magee Rehabilitation Hospital. ...
(Date:9/1/2015)... ... September 01, 2015 , ... e-Spirit Inc., a leading supplier ... FirstSpirit Content Management System with new capabilities and enhancements designed to support the ... will be well on their way to achieving digital transformation with less time ...
(Date:9/1/2015)... ... 2015 , ... The FSH Society , the Massachusetts-based charity that has ... be the beneficiary of a collection of fundraising events this fall. From Boston to ... FSH Society and further FSHD research. , The list of 2015 fall ...
Breaking Medicine News(10 mins):Health News:Survey: Consumers Prefer ASDS Members 2Health News:Survey: Consumers Prefer ASDS Members 3Health News:Beauty Entrepreneur creates hair extension smart machine and mobile app inspired by UBER technology 2Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 2Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 3Health News:e-Spirit boosts Corporate Content Cloud initiative with release of FirstSpirit 5.2 2Health News:e-Spirit boosts Corporate Content Cloud initiative with release of FirstSpirit 5.2 3Health News:FSH Society Beneficiary of Variety of Fall Fundraising Events 2Health News:FSH Society Beneficiary of Variety of Fall Fundraising Events 3
... SWEDESBORO, N.J., Oct. 1 Wedgewood Pharmacy ... entered an agency agreement,through which Midwest will ... clinics in 27 states. The relationship is,effective ... that Midwest has represented a,compounding pharmacy service. ...
... Attorneys from McKissock & Hoffman, PHILADELPHIA, Oct. ... Cherin and Mellott, LLC today announced that it ... of 22 attorneys from,McKissock & Hoffman including name ... in the continued expansion of Eckert Seamans, Philadelphia,and ...
... a supplier,of affordable medical imaging systems to healthcare providers, ... president of Sales,and Business Development for the company. ... to the,next level," says Tom Hacking, chairman and chief ... forward to the many contributions he,will make." With ...
... Educational ... Resource at IDSA Annual Meeting, HADDON HEIGHTS, N.J., Oct. ... continuing education,resource as part of their exhibit booth at the ... October 4-7, in San Diego,California. Project CDAD: Outbreak Prevention and ...
... pinch in the arm can help save 36,000 lives ... the,beginning of flu season, which will put up to ... is easily prevented with an inexpensive,vaccination. AARP is urging ... begins its annual spread., (Logo: http://www.newscom.com/cgi-bin/prnh/20070209/NYF043LOGO ...
... 1 BD (Becton,Dickinson and Company) (NYSE: BDX ... of its fourth fiscal quarter 2007 earnings conference call ... will issue a press,release detailing the quarter,s earnings earlier ... will be accessible through BD,s,website at http://www.bd.com/investors ...
Cached Medicine News:Health News:Wedgewood Pharmacy and Midwest Veterinary Supply Sign New Agency Agreement 2Health News:Wedgewood Pharmacy and Midwest Veterinary Supply Sign New Agency Agreement 3Health News:Eckert Seamans Announces Major Expansion in Philadelphia, West Chester and Harrisburg 2Health News:Eckert Seamans Announces Major Expansion in Philadelphia, West Chester and Harrisburg 3Health News:National Experts Team Up to Help Hospitals Prevent and Control C. difficile Outbreaks 2Health News:AARP Reminds All People 50-Plus to Get a Flu Shot This Year 2
The First Check Home Drug Test is the first over-the counter, FDA approved home drug test that provides immediate information about the possible use of prescription drugs....
PediaVision LLC is a life sciences company dedicated to solving the critical problem of undiagnosed vision problems affecting children worldwide....
... the treatment of presbyopia, a condition that affects ... patients. , Presbyopia results from the gradual loss ... eye as a person ages, making the lens ... eye has a harder time focusing on objects ...
Designed with your input, the ATS Simulus™ flexible annuloplasty ring and band are easy endings to complex mitral valve repairs....
Medicine Products: